Added value of this study
ADENOVIRUS, RVF, DISEASE, ADVERSE EVENTS
This study describes a first-in-human trial of ChAdOx1 RVF, a chimpanzee adenovirus vectored RVF vaccine that has been shown to be highly immunogenic and efficacious against RVF in all major livestock species affected by the disease. While the ChAdOx1 platform is widely deployed for use against COVID-19 (Oxford/AstraZeneca AZD1222 vaccine) in over 180 countries globally, this is the first clinical evaluation of its use for RVF in humans. We assessed the safety and immunogenicity of a single intramuscular dose of ChAdOx1 RVF among adults in the UK. ChAdOx1 RVF was well tolerated with no serious adverse events. High RVF nAb titres were detected within 2 weeks of vaccination, peaking at 28 days post-vaccination. A strong RVF viral glycoprotein-specific IFNγ response, peaking 2 weeks post-vaccination, was also detected. Both humoral and cellular responses persisted over the 3 months follow up period of the study.